TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

TP53 alterations independently predicted inferior remission, EFS, and OS after CAR T-cell therapy in relapsed/refractory B-ALL.

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...

TP53 aberrations have been used as prognostic markers and can inform treatment decision making for patients with CLL. TP53 aberrations should be assessed prior to each treatment decision, according to ...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew ...

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found. The findings were reported in the ...

The TP53 is a gene that instructs the cell to produce tumor protein (p53) ; a vital transcription factor and tumor suppressor. P53 is known as the “guardian of the genome” as it helps in regulating ...

—A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that patients with wild type TP53 had longer time to first treatment and ...

A rare, African-specific variant of the TP53 gene called P47S causes iron accumulation in macrophages and other cell types and is associated with poorer response to bacterial infections, along with ...